This past year has seen more gene therapies approved by the FDA than the previous five years combined, and almost triple the number of clinical trials in gene therapy have been initiated in H1 of 2023 compared to the same time frame in the previous year.

To maximize the value of your late-stage gene therapy assets, the 7^th Gene Therapy for Rare Disorders Summit is returning to tackle head-on the significant clinical, manufacturing, regulatory, and commercial challenges facing gene therapy programs today.

Bringing together key figures from industry, regulatory bodies, patient non-profits, payers, and key service providers, this is the field’s foremost meeting for collectively progressing rare gene therapy programs into and through the clinic.

Join us to leverage essential insights from over 300 peers from leading biopharma companies with direct experience in driving gene therapies through the clinic and into the market. Keep your finger on the pulse, form connections with top decision-makers, and address your specific clinical, manufacturing, regulatory, and commercial bottlenecks to safeguard against costly delays and progress your gene therapies through the pipeline quickly and safely.

To know more visit: https://ter.li/x4qqur